Website: https://www.tradewindbio.com/
Develops targeted cancer therapies by focusing on a unique oncogene, which produces a secreted protein highly expressed in cancer cells but not adult tissues, correlating with cancer aggressiveness.
VentureRadar Research / Company Website
Tradewind scientists have identified an oncogene that is a little different than the mutated kinases and amplified genes we normally think of as oncogenes. Our first drug target is a secreted protein, that comes to be highly expressed in cancer cells, whereas it is not expressed in adult tissues. It can initiate cancer in transgenic mouse models, enable ascites growth and dissemination to distant organs and is important to maintain tumor cell survival and proliferation in tumors that evolve high expression. Expression correlates with the aggressiveness of human cancer.
VentureRadar Research / Company Website
Associated sectors:
Biotechnology; Antibodies; Drug Discovery; Immuno-oncology; Biologics;
Similar Companies:
Aulos Bioscience
USA
Privately Held
Aulos Bioscience is dedicated to revolutionizing patient care in cancer with highly differentiated immuno-oncology therapeutics. Aulos was created by ATP, a leading life science venture capital firm, and Biolojic Design, a biotechnology company that computationally designs functional antibodies, to initially develop unique IL-2 targeting antibodies that it believes have the potential to become best-in-class treatments for solid tumors.
Alloy Therapeutics
USA
Privately Held
Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, we democratize access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. We provide affordable, non-exclusive access to the entire drug discovery community from academic scientists, small and medium biotech, to the largest biopharma.
Nectin
Israel
Privately Held
Nectin Therapeutics is an early-stage company established in 2017 based on a collaboration of the Hebrew University of Jerusalem and the University of Rijeka, Croatia. At Nectin, we are dedicated to the development of novel therapeutic options for cancer patients. We are developing a diverse pipeline of targeted antibodies that overcome inhibitory pathways deployed by the tumors and allow immune cells to effectively destroy cancer cells. Additionally, based on the unique expression patterns of several nectin proteins, we develop CAR-T and -NK drivers that directly target tumor cells in various indications, including hard-to-treat cancers.
BIOMUNEX
France
Privately Held
BIOMUNEX Pharmaceuticals is a biopharmaceutical company focused on developing therapeutics in the area of immuno-oncology through the discovery and development of innovative bispecific antibodies. We develop cutting-edge immunotherapies for several cancer types with our unique proprietary BiXAb bispecific antibody platform. The BiXAb platform can also generate innovative bispecific antibodies in any other therapeutic areas, such as immune-mediated inflammatory diseases or infectious diseases or any other diseases in which therapeutic bispecific antibodies may provide benefit.
Humanigen
USA
n/a
We are a clinical stage biopharmaceutical company, developing our immunology and immuno-oncology portfolio of monoclonal antibodies. We are focusing our efforts on the development of our lead product candidate, lenzilumab, our proprietary Humaneered® (“Humaneered”) anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody. Lenzilumab is a monoclonal antibody that has been proven in animal models to neutralize GM-CSF, a cytokine that we believe is of critical importance in the hyperinflammatory cascade, sometimes referred to as cytokine release syndrome (“CRS”) or cytokine storm, associated with COVID-19, chimeric antigen receptor T-cell (“CAR-T”) therapy and acute Graft versus Host Disease (“GvHD”) associated with bone marrow transplants. Lenzilumab binds to and neutralizes GM-CSF.